These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20513156)

  • 1. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
    Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
    J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
    Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
    Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
    O'Hare T; Shakespeare WC; Zhu X; Eide CA; Rivera VM; Wang F; Adrian LT; Zhou T; Huang WS; Xu Q; Metcalf CA; Tyner JW; Loriaux MM; Corbin AS; Wardwell S; Ning Y; Keats JA; Wang Y; Sundaramoorthi R; Thomas M; Zhou D; Snodgrass J; Commodore L; Sawyer TK; Dalgarno DC; Deininger MW; Druker BJ; Clackson T
    Cancer Cell; 2009 Nov; 16(5):401-12. PubMed ID: 19878872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
    Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
    Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
    Thomas M; Huang WS; Wen D; Zhu X; Wang Y; Metcalf CA; Liu S; Chen I; Romero J; Zou D; Sundaramoorthi R; Li F; Qi J; Cai L; Zhou T; Commodore L; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Iuliucci J; Rivera VM; Sawyer TK; Dalgarno DC; Clackson T; Shakespeare WC
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3743-8. PubMed ID: 21561767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Candidate Containing an (
    Zhang D; Li P; Gao Y; Song Y; Zhu Y; Su H; Yang B; Li L; Li G; Gong N; Lu Y; Shao H; Yu C; Huang H
    J Med Chem; 2021 Jun; 64(11):7434-7452. PubMed ID: 34011155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
    Li Y; Shen M; Zhang Z; Luo J; Pan X; Lu X; Long H; Wen D; Zhang F; Leng F; Li Y; Tu Z; Ren X; Ding K
    J Med Chem; 2012 Nov; 55(22):10033-46. PubMed ID: 23088644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-((3-amino-
    El-Damasy AK; Kim HJ; Park JW; Nam Y; Hur W; Bang EK; Keum G
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2228515. PubMed ID: 37470410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design.
    Park H; Hong S; Kim J; Hong S
    J Am Chem Soc; 2013 Jun; 135(22):8227-37. PubMed ID: 23679864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
    Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
    Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.
    Hong S; Kim J; Yun SM; Lee H; Park Y; Hong SS; Hong S
    J Med Chem; 2013 May; 56(9):3531-45. PubMed ID: 23600806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
    Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
    Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
    Ren X; Pan X; Zhang Z; Wang D; Lu X; Li Y; Wen D; Long H; Luo J; Feng Y; Zhuang X; Zhang F; Liu J; Leng F; Lang X; Bai Y; She M; Tu Z; Pan J; Ding K
    J Med Chem; 2013 Feb; 56(3):879-94. PubMed ID: 23301703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation.
    Wang S; Chen J; Hou R; Xiong Y; Shi H; Chen Z; Li J; Wang X
    Chem Biol Interact; 2024 Nov; 403():111248. PubMed ID: 39332790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
    Yuan X; Zhang Y; Zhang H; Jin J; Li X; Liu H; Feng Z; Chen X
    Leuk Res; 2011 Feb; 35(2):237-42. PubMed ID: 20739063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
    Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
    Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.